title: PK11195 headfold at 4.5h

description:
Date	2/15/2002
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	PK11195
Route :	single i.p. injection
Dose :	4.0 mg/kg
Time :	4.5 hrs post-injection
Intervention :	none
Risk: no increased risk for microphthalmia
Conditional biomarker: p53 protein induction not observed or anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	4800 element array less 36 control spots and averaging of duplicated elements resulting in 2382 spots

Keywords = PK11195
Keywords = embryo
Keywords = threshold
Lot batch = SA971

source_name: 4.0 mg/kg PK11195 headfold

source_name: saline - control headfold


title: EtOH at 3.0h in C57BL/6J mice

status: Public on Mar 11 2004

type: RNA

city: Louisville

first: Thomas

middle: B

last: Knudsen

state: KY

address: 501 S Preston St

department: Birth Defects Center

country: USA

institute: University of Louisville

description:
Date :	1/21/2003
Original sample
Species :	Mouse
Strain :	C57BL/6J
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	ethanol
Route :	single i.p. injection
Dose :	2.9 g/kg
Time :	3 hrs post-injection
Intervention :	none
Risk: <20% estimated risk for alcohol-related birth defects
Conditional biomarker: no p53 protein induction observed
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	4800 element array less 36 control spots and averaging of duplicated elements resulting in 2382 spots

Keywords = ethanol
Keywords = alcohol-related birth defects
Keywords = FAS
Keywords = genetic susceptibility
Lot batch = SE257

molecule: total RNA

organism: Mus musculus

source_name: 2.9 g/kg ethanol headfold at 3.0h

source_name: saline - control headfold, C57BL/6J


title: Ro5-4864 headfold at 4.5h

description:
Date	1/21/2002
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	Ro5-4864
Route :	single i.p. injection
Dose :	4.0 mg/kg
Time :	4.5 hrs post-injection
Intervention :	none
Risk: 15% microphthalmia
Conditional biomarker: weak p53 protein induction
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	4800 element array less 36 control spots and averaging of duplicated elements resulting in 2382 spots

Keywords = Ro5-4864
Keywords = embryo
Keywords = microphthalmia
Lot batch = SA927

source_name: 4.0 mg/kg Ro5-4864 headfold


title: PK11195 headfold at 4.5h

description:
Date	2/15/2002
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	PK11195
Route :	single i.p. injection
Dose :	4.0 mg/kg
Time :	4.5 hrs post-injection
Intervention :	none
Risk: no increased risk for microphthalmia
Conditional biomarker: no p53 protein induction observed or anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	4800 element array less 36 control spots and averaging of duplicated elements resulting in 2382 spots

Keywords = PK11195
Keywords = embryo
Keywords = threshold
Lot batch = SA973


title: Ro5-4864 headfold at 4.5h

description:
Date	1/21/2002
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	Ro5-4864
Route :	single i.p. injection
Dose :	4.0 mg/kg
Time :	4.5 hrs post-injection
Intervention :	none
Risk: 15% microphthalmia
Conditional biomarker: weak p53 protein induction
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	4800 element array less 36 control spots and averaging of duplicated elements resulting in 2382 spots

Keywords = Ro5-4864
Keywords = embryo
Keywords = microphthalmia
Lot batch = SA926


title: 2CdA: PK11195 intervention at 6.0h

description:
Date	2/26/2001
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	2.5 mg/kg
Time :	6.0 hrs post-injection
Intervention :	4.0 mg/kg PK11195 co-administered
Risk: remediated
Conditional biomarker: no p53 protein induction anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = PK11195
Keywords = embryo
Keywords = microphthalmia
Lot batch = AM079

source_name: 2.5 mg/kg 2CdA + PK11195 headfold

source_name: 2CdA treated headfold


title: 2CdA: PK11195 intervention at 6.0h

description:
Date	3/26/2001
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	2.5 mg/kg
Time :	6.0 hrs post-injection
Intervention :	4.0 mg/kg PK11195 co-administered
Risk: remediated
Conditional biomarker: no p53 protein induction anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = PK11195
Keywords = embryo
Keywords = microphthalmia
Lot batch = AN997


title: 2CdA: PK11195 intervention at 4.5h

description:
Date	3/9/2001
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	2.5 mg/kg
Time :	4.5 hrs post-injection
Intervention :	4.0 mg/kg PK11195 co-administered
Risk: remediated
Conditional biomarker: no p53 protein induction observed or anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots
Keywords = 2-chlorodeoxyadenosine
Keywords = PK11195
Keywords = embryo
Keywords = microphthalmia
Lot batch = AM040


title: 2CdA: PK11195 intervention at 3.0h

description:
Date	2/26/2001
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	2.5 mg/kg
Time :	3.0 hrs post-injection
Intervention :	4.0 mg/kg PK11195 co-administered
Risk: remediated
Conditional biomarker: no p53 protein induction observed or anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = PK11195
Keywords = embryo
Keywords = microphthalmia
Lot batch = AM039


title: 2CdA: PK11195 intervention at 3.0h

description:
Date	3/16/2001
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	2.5 mg/kg
Time :	3.0 hrs post-injection
Intervention :	4.0 mg/kg PK11195 co-administered
Risk: remediated
Conditional biomarker: no p53 protein induction observed or anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = PK11195
Keywords = embryo
Keywords = microphthalmia
Lot batch = AM080


title: 2.5 mg/kg 2CdA headfold at 4.5h

description:
Date	2/5/2001
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	2.5 mg/kg
Time :	4.5 hrs post-injection
Intervention :	none
Risk: benchmark dose modeled for 5% increased risk of microphthalmia
Conditional biomarker: post-injection interval at the time of p53 protein induction
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = embryo
Keywords = microphthalmia
Lot batch = AM035


title: 2.5 mg/kg 2CdA headfold at 6.0h

description:
Date	2/13/2001
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	2.5 mg/kg
Time :	6.0 hrs post-injection
Intervention :	none
Risk: benchmark dose modeled for 5% increased risk of microphthalmia
Conditional biomarker: post-injection interval beyond p53 protein induction
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = embryo
Keywords = microphthalmia
Lot batch = AM036


title: 5.0 mg/kg 2CdA embryo at 3.0h

description:
Date	11/16/2000
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	embryo proper
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	5.0 mg/kg
Time :	3 hrs post-injection
Intervention :	none
Risk: 25% increased risk of microphthalmia
Conditional biomarker: p53 protein induction observed or anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	8-10 embryos pooled from same litter
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	dinitrophenol-11-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-DNP with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = embryo
Keywords = microphthalmia
Lot batch = AH593

source_name: 2-chloro-2'-deoxyadenosine treated

source_name: saline - control


title: 1.25 mg/kg 2CdA embryo at 3.0h

description:
Date	9/22/2000
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	embryo proper
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	1.25 mg/kg
Time :	3 hrs post-injection
Intervention :	none
Risk: NOAEL (no increased risk of malformation)
Conditional biomarker: p53 protein induction not observed or anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	8-10 embryos pooled from same litter
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	dinitrophenol-11-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-DNP with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = embryo
Lot batch = AG627


title: 2.5 mg/kg 2CdA headfold at 3.0h

description:
Date	3/26/2001
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	2.5 mg/kg
Time :	3.0 hrs post-injection
Intervention :	none
Risk: benchmark dose modeled for 5% increased risk of microphthalmia
Conditional biomarker: post-injection interval prior to p53 protein induction
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = embryo
Keywords = microphthalmia
Lot batch = AN961


title: 2.5 mg/kg 2CdA headfold at 4.5h

description:
Date	3/29/2001
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	2.5 mg/kg
Time :	4.5 hrs post-injection
Intervention :	none
Risk: benchmark dose modeled for 5% increased risk of microphthalmia
Conditional biomarker: post-injection interval at the time of p53 protein induction
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = embryo
Keywords = microphthalmia
Lot batch = AN962


title: 2.5 mg/kg 2CdA embryo at 3.0h

description:
Date	9/12/2000
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	embryo proper
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	2.5 mg/kg
Time :	3 hrs post-injection
Intervention :	none
Risk: benchmark dose modeled for 5% increased risk of microphthalmia
Conditional biomarker: weak p53 protein induction observed or anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	8-10 embryos pooled from same litter
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	dinitrophenol-11-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-DNP with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = embryo
Keywords = threshold
Lot batch = AG681


title: 2.5 mg/kg 2CdA headfold at 6.0h

description:
Date	3/29/2001
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	2.5 mg/kg
Time :	6.0 hrs post-injection
Intervention :	none
Risk: benchmark dose modeled for 5% increased risk of microphthalmia
Conditional biomarker: post-injection interval beyond p53 protein induction
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = embryo
Keywords = microphthalmia
Lot batch = AN914


title: 2CdA: PK11195 intervention at 4.5h

description:
Date	3/16/2001
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	2.5 mg/kg
Time :	4.5 hrs post-injection
Intervention :	4.0 mg/kg PK11195 co-administered
Risk: remediated
Conditional biomarker: no p53 protein induction observed or anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = PK11195
Keywords = embryo
Keywords = microphthalmia
Lot batch = AN996


title: 2.5 mg/kg 2CdA headfold at 3.0h

description:
Date	1/19/2001
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	headfold
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	2.5 mg/kg
Time :	3.0 hrs post-injection
Intervention :	none
Risk: benchmark dose modeled for 5% increased risk of microphthalmia
Conditional biomarker: post-injection interval prior to p53 protein induction
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	16-20 headfolds pooled from two litters
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	fluorescein-12-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-FL with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = embryo
Keywords = threshold
Lot batch = AH606


title: 2.5 mg/kg 2CdA embryo at 3.0h

description:
Date	9/12/2000
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	embryo proper
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	2.5 mg/kg
Time :	3 hrs post-injection
Intervention :	none
Risk: benchmark dose modeled for 5% increased risk of microphthalmia
Conditional biomarker: weak p53 protein induction observed or anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	8-10 embryos pooled from same litter
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	dinitrophenol-11-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-DNP with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = embryo
Keywords = threshold
Lot batch = AG680


title: 5.0 mg/kg 2CdA embryo at 3.0h

description:
Date	3/10/2000
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	embryo proper
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	5.0 mg/kg
Time :	3 hrs post-injection
Intervention :	none
Risk: 25% increased risk of microphthalmia
Conditional biomarker: p53 protein induction observed or anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	8-10 embryos pooled from same litter
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	dinitrophenol-11-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-DNP with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = embryo
Keywords = microphthalmia
Lot batch = AE195


title: 0.625 mg/kg 2CdA embryo at 3.0h

description:
Date	11/30/2000
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	embryo proper
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	0.625 mg/kg
Time :	3 hrs post-injection
Intervention :	none
Risk: subNOAEL (no increased risk of malformation)
Conditional biomarker: p53 protein induction not observed or anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	8-10 embryos pooled from same litter
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	dinitrophenol-11-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-DNP with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = embryo
Lot batch = AI057


title: 0.625 mg/kg 2CdA embryo at 3.0h

description:
Date	11/30/2000
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	embryo proper
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	0.625 mg/kg
Time :	3 hrs post-injection
Intervention :	none
Risk: subNOAEL (no increased risk of malformation)
Conditional biomarker: p53 protein induction not observed or anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	8-10 embryos pooled from same litter
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	dinitrophenol-11-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-DNP with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = embryo
Lot batch = AI058


title: 1.25 mg/kg 2CdA embryo at 3.0h

description:
Date	9/22/2000
Original sample
Species :	Mouse
Strain :	CD-1 (outbred)
Genotype :	wild-type
Stage :	8 d.p.c., Theiler stage 12
Tissue :	embryo proper
Treatments applied
Agent :	2-chloro-2'-deoxyadenosine
Route :	single i.p. injection
Dose :	1.25 mg/kg
Time :	3 hrs post-injection
Intervention :	none
Risk: NOAEL (no increased risk of malformation)
Conditional biomarker: p53 protein induction not observed or anticipated
Technical extraction & labeling
Tissue procurement :	conventional microdissection
Sampling unit :	8-10 embryos pooled from same litter
Hybridization extract preparation :	2-4 ug total cellular RNA (Qiagen RNeasy kit Cat. 74103)
Labeling (cDNA) :	dinitrophenol-11-dCTP, biotinyl-11-dCTP
Hybridization condition :	56oC, overnight, stringency washes 0.5X SSC, 0.1% SDS, 0.06X SSC, 0.01% SDS, and 0.06X SSC
Detection & raw data organization
Immunodetection :	anti-DNP with Cy3-tyramide,  peroxidase-conjugated streptavidin with Cy5-tyramide
Scanning :	Micromax Custom Scanning and Data Processing Service (PerkinElmer Life Sciences, Cat.MPS401), Cy3 channel 532 nm and Cy5 channel 635 nm
Spot measurement :	ImaGene Method 1: Calculates average intensity of all pixels within the circle with intensity values falling in the predetermined range (e.g., 50% - 95% of maximal intensity in a grid square of a spot).
Background correction :	The background is calculated from the background range of pixels (e.g., 5-15% of maximal intensities) between the background rings. Local background is the subtracted from signal from every spot and every channel separately.
Gene expression matrix :	2400 element array less 12 control spots and 6 spots from incomplete printing resulting in 2382 spots

Keywords = 2-chlorodeoxyadenosine
Keywords = embryo
Lot batch = AG626


title: unloaded healing 1

status: Public on Mar 10 2004

city: Houston

first: Steven

last: Strasnick

state: TX

address: 369 Science and Research Bldg. II

department: Dept. of Biology and Biochemistry

institute: University of Houston

description: Unloaded wound healing group animals underwent bilateral disruption of the medial collateral ligament and were subjected to hindlimb unloading using the tail suspension protocol of the NASA Ames Research Center 24 hours after surgery. After 3 weeks the animals were euthanized and the medical collateral ligaments were dissected free.

organism: Rattus norvegicus

source_name: medial collateral ligament


title: unloaded control 2

description: Unloaded control group animals underwent no sham surgery and were subjected to hindlimb unloading using the tail suspension protocol of the NASA Ames Research Center. After 3 weeks the animals were euthanized and the medical collateral ligaments were dissected free.


title: loaded healing 2

description: Loaded wound healing group animals underwent bilateral disruption of the medial collateral ligament. After 3 weeks the animals were euthanized and the medial collateral ligaments were dissected free.


title: loaded healing 1


title: Control_1.2 (a) AG

status: Public on Mar 09 2004

city: Rockville

first: Julia

middle: C

last: Redman

state: MD

address: 9712 Medical Center Dr

department: Plant Genomics

institute: The Institute for Genomic Research

description:
Untreated control, hybridization 2; scaling factor 3.6. Same sample hybridized also to ATH1 probe array  (refer to series GSE1110 and data GSM18228 and 18229).  See series file for additional information.
Keywords = IAA
Keywords = whole plant
Keywords = indole-3-acetic acid

organism: Arabidopsis thaliana

source_name: whole plant, WT Col-0


title: 0.1uM_IAA_1h_1.1 AG

description:
Exposure to 0.1micromolar IAA for 1h prior to harvest, hybridization 1; scaling factor 3.7.  Same sample hybridized also to ATH1 probe array  (refer to series GSE1110 and data GSM18290 and 18291).  See series file for additional information.
Keywords = IAA
Keywords = whole plant
Keywords = indole-3-acetic acid


title: Primary combined SCLC-AD 4544

city: Koto-ku

first: Yuichi

last: Ishikawa

state: Tokyo

address: 3-8-31 Ariake

country: Japan

institute: Cancer Insitute

description: Primary combined SCLC-AD 4544

organism: Homo sapiens

source_name: Primary combined SCLC-AD 4544

source_name: lung reference


title: 0.1uM_IAA_3h_1.1 AG

description:
Exposure to 0.1micromolar IAA for 3h prior to harvest, hybridization 1; scaling factor 5.0.  Same sample hybridized also to ATH1 probe array  (refer to series GSE1110 and data GSM18294 and 18295).  See series file for additional information.
Keywords = IAA
Keywords = whole plant
Keywords = indole-3-acetic acid


title: Primary combined SCLC-AD 1870

description: Primary large cell lung carcinoma 1870

source_name: Primary combined SCLC-AD 1870


title: Control_1.1 (a) AG

description:
Untreated control, hybridization 1; scaling factor 3.3. Same sample hybridized also to ATH1 probe array  (refer to series GSE1110 and data GSM18228 and 18229).  See series file for additional information.

Keywords = IAA
Keywords = whole plant
Keywords = indole-3-acetic acid


title: loaded control 2

description: Loaded sham control group animals underwent sham control surgery. After 3 weeks the animals were euthanized and the medial collateral ligaments were dissected free.


title: 0.1uM_IAA_3h_1.2 AG

description:
Exposure to 0.1micromolar IAA for 3h prior to harvest, hybridization 2; scaling factor 5.0.  Same sample hybridized also to ATH1 probe array  (refer to series GSE1110 and data GSM18294 and 18295).  See series file for additional information.
Keywords = IAA
Keywords = whole plant
Keywords = indole-3-acetic acid


title: unloaded healing 2


title: unloaded control 1

description:
Unloaded control group animals underwent no sham surgery and were subjected to hindlimb unloading using the tail suspension protocol of the NASA Ames Research Center. After 3 weeks the animals were euthanized and the medical collateral
ligaments were dissected free.


title: Primary large cell carcinoma 1485

description: Primary large cell lung carcinoma 1485

source_name: Primary large cell carcinoma 1485


title: 0.1uM_IAA_1h_1.2 AG

description:
Exposure to 0.1micromolar IAA for 1h prior to harvest, hybridization 2; scaling factor 4.4. Same sample hybridized also to ATH1 probe array  (refer to series GSE1110 and data GSM18290 and 18291).  See series file for additional information.
Keywords = IAA
Keywords = whole plant
Keywords = indole-3-acetic acid


title: Primary large cell carcinoma 525

description: Primary large cell lung carcinoma 525

source_name: Primary large cell carcinoma 525


title: Primary large cell carcinoma 1997

description: Primary large cell lung carcinoma 1997

source_name: Primary large cell carcinoma 1997


title: Primary large cell carcinoma 745

description: Primary large cell lung carcinoma 745

source_name: Primary large cell carcinoma 745


title: loaded control 1


title: LPS and LPS-binding protein treated RAW 264.7 cells 48 hours vs Untreated RAW 264.7 cells 48 hours (set 2)

status: Public on Mar 05 2004

city: Pasadena

first: Sangdun

last: Choi

state: CA

address: 1200 E. California Blvd

department: Biology

institute: California Institute of Technology

description:
All samples were gathered from mouse RAW 264.7 cells (macrophages). Control total RNA was extracted from lipopolysaccharide (100ng/ml) and lipopolysaccharide-binding protein (100pM) treated RAW 264.7 cells cultured for 48 hours.
All samples were gathered from mouse RAW 264.7 cells (macrophages). Test total RNA was extracted from untreated RAW 264.4 cells cultured for 48 hours.

source_name: Total RNA from lipopolysaccharide (100ng/ml) and lipopolysaccharide-binding protein (100pM) treated RAW 264.7 cells was labeled with Cyanine-3 (green).

source_name: Total RNA from untreated RAW 264.7 cells was labeled with Cyanine-5 (red).


title: LPS and LPS-binding protein treated RAW 264.7 cells 48 hours vs Untreated RAW 264.7 cells 48 hours (set 1)


title: Primary large cell carcinoma 1531

description: Primary large cell lung carcinoma 1531

source_name: Primary large cell carcinoma 1531


title: LPS and LPS-binding protein treated RAW 264.7 cells 16 hours vs Untreated RAW 264.7 cells 16 hours (set 3)

description:
All samples were gathered from mouse RAW 264.7 cells (macrophages). Control total RNA was extracted from lipopolysaccharide (100ng/ml) and lipopolysaccharide-binding protein (100pM) treated RAW 264.7 cells cultured for 16 hours.
All samples were gathered from mouse RAW 264.7 cells (macrophages). Test total RNA was extracted from untreated RAW 264.4 cells cultured for 16 hours.


title: LPS and LPS-binding protein treated RAW 264.7 cells 48 hours vs Untreated RAW 264.7 cells 48 hours (set 3)


title: LPS and LPS-binding protein treated RAW 264.7 cells 8 hours vs Untreated RAW 264.7 cells 8 hours (set 2)

description:
All samples were gathered from mouse RAW 264.7 cells (macrophages). Control total RNA was extracted from lipopolysaccharide (100ng/ml) and lipopolysaccharide-binding protein (100pM) treated RAW 264.7 cells cultured for 8 hours.
All samples were gathered from mouse RAW 264.7 cells (macrophages). Test total RNA was extracted from untreated RAW 264.4 cells cultured for 8 hours.


title: LPS and LPS-binding protein treated RAW 264.7 cells 8 hours vs Untreated RAW 264.7 cells 8 hours (set 3)


title: LPS and LPS-binding protein treated RAW 264.7 cells 16 hours vs Untreated RAW 264.7 cells 16 hours (set 2)


title: LPS and LPS-binding protein treated RAW 264.7 cells 16 hours vs Untreated RAW 264.7 cells 16 hours (set 1)


title: LPS and LPS-binding protein treated RAW 264.7 cells 4 hours vs Untreated RAW 264.7 cells 4 hours (set 2)

description:
All samples were gathered from mouse RAW 264.7 cells (macrophages). Control total RNA was extracted from lipopolysaccharide (100ng/ml) and lipopolysaccharide-binding protein (100pM) treated RAW 264.7 cells cultured for 4 hours.
All samples were gathered from mouse RAW 264.7 cells (macrophages). Test total RNA was extracted from untreated RAW 264.4 cells cultured for 4 hours.


title: LPS and LPS-binding protein treated RAW 264.7 cells 4 hours vs Untreated RAW 264.7 cells 4 hours (set 3)


title: Untreated RAW 264.7 cells 16 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 16 hours (set 3)

description:
All samples were gathered from mouse RAW 264.7 cells (macrophages). Control total RNA was extracted from untreated RAW 264.7 cells cultured for 16 hours.
All samples were gathered from mouse RAW 264.7 cells (macrophages). Test total RNA was extracted from lipopolysaccharide (100ng/ml) and lipopolysaccharide-binding protein (100pM) treated RAW 264.4 cells cultured for 16 hours.

source_name: Total RNA from untreated RAW 264.7 cells was labeled with Cyanine-3 (green).

source_name: Total RNA from lipopolysaccharide (100ng/ml) and lipopolysaccharide-binding protein (100pM) treated RAW 264.7 cells was labeled with Cyanine-5 (red).


title: LPS and LPS-binding protein treated RAW 264.7 cells 1 hour vs Untreated RAW 264.7 cells 1 hour (set 1)

description:
All samples were gathered from mouse RAW 264.7 cells (macrophages). Control total RNA was extracted from lipopolysaccharide (100ng/ml) and lipopolysaccharide-binding protein (100pM) treated RAW 264.7 cells cultured for 1 hour.
All samples were gathered from mouse RAW 264.7 cells (macrophages). Test total RNA was extracted from untreated RAW 264.4 cells cultured for 1 hour.


title: LPS and LPS-binding protein treated RAW 264.7 cells 8 hours vs Untreated RAW 264.7 cells 8 hours (set 1)


title: Untreated RAW 264.7 cells 48 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 48 hours (set 3)

description:
All samples were gathered from mouse RAW 264.7 cells (macrophages). Control total RNA was extracted from untreated RAW 264.7 cells cultured for 48 hours.
All samples were gathered from mouse RAW 264.7 cells (macrophages). Test total RNA was extracted from lipopolysaccharide (100ng/ml) and lipopolysaccharide-binding protein (100pM) treated RAW 264.4 cells cultured for 48 hours.


title: LPS and LPS-binding protein treated RAW 264.7 cells 4 hours vs Untreated RAW 264.7 cells 4 hours (set 1)


title: LPS and LPS-binding protein treated RAW 264.7 cells 1 hour vs Untreated RAW 264.7 cells 1 hour (set 2)


title: LPS and LPS-binding protein treated RAW 264.7 cells 2 hours vs Untreated RAW 264.7 cells 2 hours (set 1)

description:
All samples were gathered from mouse RAW 264.7 cells (macrophages). Control total RNA was extracted from lipopolysaccharide (100ng/ml) and lipopolysaccharide-binding protein (100pM) treated RAW 264.7 cells cultured for 2 hours.
All samples were gathered from mouse RAW 264.7 cells (macrophages). Test total RNA was extracted from untreated RAW 264.4 cells cultured for 2 hours.


title: Untreated RAW 264.7 cells 8 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 8 hours (set 3)

description:
All samples were gathered from mouse RAW 264.7 cells (macrophages). Control total RNA was extracted from untreated RAW 264.7 cells cultured for 8 hours.
All samples were gathered from mouse RAW 264.7 cells (macrophages). Test total RNA was extracted from lipopolysaccharide (100ng/ml) and lipopolysaccharide-binding protein (100pM) treated RAW 264.4 cells cultured for 8 hours.


title: Untreated RAW 264.7 cells 48 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 48 hours (set 2)


title: LPS and LPS-binding protein treated RAW 264.7 cells 2 hours vs Untreated RAW 264.7 cells 2 hours (set 3)


title: Untreated RAW 264.7 cells 16 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 16 hours (set 2)


title: Untreated RAW 264.7 cells 16 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 16 hours (set 1)


title: LPS and LPS-binding protein treated RAW 264.7 cells 1 hour vs Untreated RAW 264.7 cells 1 hour (set 3)


title: LPS and LPS-binding protein treated RAW 264.7 cells 2 hours vs Untreated RAW 264.7 cells 2 hours (set 2)


title: Untreated RAW 264.7 cells 4 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 4 hours (set 3)

description:
All samples were gathered from mouse RAW 264.7 cells (macrophages). Control total RNA was extracted from untreated RAW 264.7 cells cultured for 4 hours.
All samples were gathered from mouse RAW 264.7 cells (macrophages). Test total RNA was extracted from lipopolysaccharide (100ng/ml) and lipopolysaccharide-binding protein (100pM) treated RAW 264.4 cells cultured for 4 hours.


title: Untreated RAW 264.7 cells 4 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 4 hours (set 2)


title: Untreated RAW 264.7 cells 8 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 8 hours (set 1)


title: Untreated RAW 264.7 cells 48 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 48 hours (set 1)


title: Untreated RAW 264.7 cells 8 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 8 hours (set 2)


title: Untreated RAW 264.7 cells 2 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 2 hours (set 2)

description:
All samples were gathered from mouse RAW 264.7 cells (macrophages). Control total RNA was extracted from untreated RAW 264.7 cells cultured for 2 hours.
All samples were gathered from mouse RAW 264.7 cells (macrophages). Test total RNA was extracted from lipopolysaccharide (100ng/ml) and lipopolysaccharide-binding protein (100pM) treated RAW 264.4 cells cultured for 2 hours.


title: Untreated RAW 264.7 cells 4 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 4 hours (set 1)


title: Untreated RAW 264.7 cells 2 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 2 hours (set 3)


title: Uterus versus Thymus [GenomeTiling_MRK891]

status: Public on Mar 04 2004

city: Seattle

first: Stephen

middle: W

last: Edwards

state: WA

department: Research Genetics

institute: Rosetta Inpharmatics (Merck & Co.)

description:
Samples were purchased from Clontech as mRNA.
Hybridization material was generated through a random-priming amplification procedure (RP-AMP) using primers with a random sequence at the 3' end and a fixed motif at the 5' end.  shDNP256 (first strand synthesis): 5'- TAG ATG CTG TTG NNN NNN NNN -3'  shT7N9 (second strand synthesis): 5'- ACT ATA GGG AGA NNN NNN NNN -3'  1.5  g of mRNA was reverse-transcribed with Superscript II and the DP256 random primer for 20 minutes at 42 C (10 mM DTT, 50 mM Tris-HCl pH 8.3, 75 mM KCl, 8 mM MgCl2, 0.5 mM dNTPs, 5 U/ l Superscript II). The RNA was  degraded with the addition of 20 l volume of 0.5N sodium hydroxide and 0.25 M EDTA for 20 minutes at 65 C.  The single stranded cDNA was purified using a commercial kit (Qiagen Qiaquick).
The resulting product of single stranded cDNA was placed in its entirety in a second strand reaction. Second strand synthesis reactions utilized shT7N9 random primer and the Klenow fragment of DNA polymerase utilizing standard reaction conditions (37 C for 60 minutes, 0.2 mM DTT, 2.1 mM Tris-HCl pH 7.9, 2.1 mM MgCl2, 10.7 mM NaCl, 1.07 mM dNTPs, 0.1U/ l Klenow), followed by another Qiaquick purification.  Multiple polymerase chain reactions were run using 0.15  g of double stranded DNA and standard reaction conditions.  Amplification was achieved using 10 cycles of PCR with the DP256 and T7 primers (20 mM Tris-HCl pH 8.4, 50 mM KCl, 0.01 mM dNTPs, 1.5 mM MgCl2, 0.01 U/ l Taq Polymerase)  DP256: 5'- GTT CGA GAC CTC TAG ATG CTG TTG -3'  T7: 5'- AA TTA ATA CGA CTC ACT ATA GGG AGA -3'  followed by Qiaquick purification.
Further amplification was achieved using in vitro transcription reactions with X0.5  g dsDNA and T7 RNA Polymerase (7.5 mM DTT, 40 mM Tris-HCl pH 7.5, 14.25 mM MgCl2, 10 mM NaCl, 2 mM Spermidine, 125 U/ml RNAguard, 2.5 mM dNTPs, 15 U/ml IPPase, 25kU/ml T7 Polymerase) for 16 hours at 42 C. The cRNA was purified (RNeasy) and  reverse transcribed using Superscript and random 9-mers and amino-allyl dUTP (42 C for 20 minutes, 10 mM DTT, 50mM Tris-HCl pH 8.3, 75 mM KCl, 8 mM MgCl2, 0.5 mM dNTPs, 0.5 mM aa-dUTP, 5 U/ l Superscript II).
The cDNA for each channel was covalently coupled separately with Cy5 and Cy3 monoreactive fluors, respectively, in 1M sodium bicarbonate, pH 9.0, followed by quenching with 4.0 M hydroxylamine. The Cy5 and Cy3 labelled cDNAs were purified with a QIAquick PCR purification kit and the percentage dye incorporation and total cDNA yield was determined spectrophotometrically. Cy5 and Cy3 labelled cDNAs were combined and added to 2 mls 30% formamide with Herring Sperm DNA for hybridization to the microarray.
Further details can be found in Castle et al., Genome Biol 2003;4(10):R66, http://genomebiology.com/2003/4/10/R66 , Roberts CJ et al., Science 2000, 287:873-880, and Schadt, Edwards, et al., unpublished.
Normalization of single channel data is described in Ying, et al., "Identification of Chromosomal Regions Containing Transcribed Sequences Using Microarrays and Computational Methods" , 2003 Proceedings of the American Statistical Association, Biopharmaceutical Section [CD-ROM], Alexandria, VA: American Statistical Association, 2003.
Briefly, an invariant set of probes was selected based on their intensity ranks.  Then, a LOESS regression model was fit for Cy5 vs. Cy3 intensities for all probes in the invariant set.  Finally, for all probes on the array the Cy5 intensities were normalized to the corresponding Cy3 intensities using prediction values from the regression model.
Note that the normalized intensity values given here were used for all analyses reported in the accompanying paper.  The ratio values reported here were not used for the analysis described in the manuscript and are not calculated from the normalized intensity values given below.

source_name: Uterus

source_name: Thymus


title: Uterus versus Thymus [GenomeTiling_MRK896]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK891]

source_name: CL: Leukemia Chronic Myelogenous (K562)

source_name: T lymphocyte (Jurkat)


title: Testis versus Brain - thalamus [GenomeTiling_MRK896]

source_name: Testis

source_name: Brain - thalamus


title: Testis versus Brain - thalamus [GenomeTiling_MRK891]


title: Untreated RAW 264.7 cells 1 hour vs LPS and LPS-binding protein treated RAW 264.7 cells 1 hour (set 1)

description:
All samples were gathered from mouse RAW 264.7 cells (macrophages). Control total RNA was extracted from untreated RAW 264.7 cells cultured for 1 hour.
All samples were gathered from mouse RAW 264.7 cells (macrophages). Test total RNA was extracted from lipopolysaccharide (100ng/ml) and lipopolysaccharide-binding protein (100pM) treated RAW 264.4 cells cultured for 1 hour.


title: Untreated RAW 264.7 cells 2 hours vs LPS and LPS-binding protein treated RAW 264.7 cells 2 hours (set 1)


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK889]


title: Testis versus Brain - thalamus [GenomeTiling_MRK890]


title: Testis versus Brain - thalamus [GenomeTiling_MRK886]


title: Uterus versus Thymus [GenomeTiling_MRK887]


title: Uterus versus Thymus [GenomeTiling_MRK890]


title: Testis versus Brain - thalamus [GenomeTiling_MRK889]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK890]


title: Testis versus Brain - thalamus [GenomeTiling_MRK887]


title: Uterus versus Thymus [GenomeTiling_MRK885]


title: Uterus versus Thymus [GenomeTiling_MRK888]


title: Testis versus Brain - thalamus [GenomeTiling_MRK888]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK896]


title: Uterus versus Thymus [GenomeTiling_MRK889]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK888]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK886]


title: Uterus versus Thymus [GenomeTiling_MRK886]


title: Uterus versus Thymus [GenomeTiling_MRK881]


title: Untreated RAW 264.7 cells 1 hour vs LPS and LPS-binding protein treated RAW 264.7 cells 1 hour (set 2)


title: Testis versus Brain - thalamus [GenomeTiling_MRK895]


title: Testis versus Brain - thalamus [GenomeTiling_MRK881]


title: Testis versus Brain - thalamus [GenomeTiling_MRK894]


title: Untreated RAW 264.7 cells 1 hour vs LPS and LPS-binding protein treated RAW 264.7 cells 1 hour (set 3)


title: Uterus versus Thymus [GenomeTiling_MRK884]


title: Uterus versus Thymus [GenomeTiling_MRK882]


title: Uterus versus Thymus [GenomeTiling_MRK883]


title: Testis versus Brain - thalamus [GenomeTiling_MRK880]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK884]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK895]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK881]


title: Uterus versus Thymus [GenomeTiling_MRK894]


title: Testis versus Brain - thalamus [GenomeTiling_MRK883]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK879]


title: Uterus versus Thymus [GenomeTiling_MRK893]


title: Uterus versus Thymus [GenomeTiling_MRK895]


title: Testis versus Brain - thalamus [GenomeTiling_MRK893]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK887]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK894]


title: Testis versus Brain - thalamus [GenomeTiling_MRK882]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK880]


title: Uterus versus Thymus [GenomeTiling_MRK874]


title: Testis versus Brain - thalamus [GenomeTiling_MRK884]


title: Uterus versus Thymus [GenomeTiling_MRK879]


title: Testis versus Brain - thalamus [GenomeTiling_MRK885]


title: Uterus versus Thymus [GenomeTiling_MRK880]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK885]


title: Testis versus Brain - thalamus [GenomeTiling_MRK874]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK882]


title: Testis versus Brain - thalamus [GenomeTiling_MRK879]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK883]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK893]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK874]


title: Uterus versus Thymus [GenomeTiling_MRK873]


title: Testis versus Brain - thalamus [GenomeTiling_MRK871]


title: Uterus versus Thymus [GenomeTiling_MRK872]


title: Uterus versus Thymus [GenomeTiling_MRK869]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK892]


title: Testis versus Brain - thalamus [GenomeTiling_MRK873]


title: Uterus versus Thymus [GenomeTiling_MRK871]


title: Uterus versus Thymus [GenomeTiling_MRK878]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK871]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK869]


title: Testis versus Brain - thalamus [GenomeTiling_MRK892]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK865]


title: Uterus versus Thymus [GenomeTiling_MRK868]


title: Testis versus Brain - thalamus [GenomeTiling_MRK872]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK870]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK878]


title: Testis versus Brain - thalamus [GenomeTiling_MRK865]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK873]


title: Uterus versus Thymus [GenomeTiling_MRK870]


title: Testis versus Brain - thalamus [GenomeTiling_MRK870]


title: Uterus versus Thymus [GenomeTiling_MRK865]


title: Testis versus Brain - thalamus [GenomeTiling_MRK878]


title: Testis versus Brain - thalamus [GenomeTiling_MRK866]


title: Uterus versus Thymus [GenomeTiling_MRK877]


title: Testis versus Brain - thalamus [GenomeTiling_MRK869]


title: Uterus versus Thymus [GenomeTiling_MRK866]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK872]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK877]


title: Uterus versus Thymus [GenomeTiling_MRK863]


title: Testis versus Brain - thalamus [GenomeTiling_MRK875]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK866]


title: Testis versus Brain - thalamus [GenomeTiling_MRK876]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK864]


title: Uterus versus Thymus [GenomeTiling_MRK864]


title: Uterus versus Thymus [GenomeTiling_MRK856]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK868]


title: Uterus versus Thymus [GenomeTiling_MRK876]


title: Uterus versus Thymus [GenomeTiling_MRK853]


title: Testis versus Brain - thalamus [GenomeTiling_MRK853]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK876]


title: Uterus versus Thymus [GenomeTiling_MRK875]


title: Testis versus Brain - thalamus [GenomeTiling_MRK856]


title: Uterus versus Thymus [GenomeTiling_MRK854]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK867]


title: Testis versus Brain - thalamus [GenomeTiling_MRK862]


title: Testis versus Brain - thalamus [GenomeTiling_MRK863]


title: Testis versus Brain - thalamus [GenomeTiling_MRK864]


title: Uterus versus Thymus [GenomeTiling_MRK862]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK862]


title: Uterus versus Thymus [GenomeTiling_MRK892]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK856]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK863]


title: Uterus versus Thymus [GenomeTiling_MRK867]


title: Testis versus Brain - thalamus [GenomeTiling_MRK868]


title: Testis versus Brain - thalamus [GenomeTiling_MRK867]


title: Testis versus Brain - thalamus [GenomeTiling_MRK854]


title: Testis versus Brain - thalamus [GenomeTiling_MRK877]


title: Testis versus Brain - thalamus [GenomeTiling_MRK857]


title: Uterus versus Thymus [GenomeTiling_MRK861]


title: Testis versus Brain - thalamus [GenomeTiling_MRK855]


title: Testis versus Brain - thalamus [GenomeTiling_MRK861]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK857]


title: Uterus versus Thymus [GenomeTiling_MRK860]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK849]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK861]


title: Uterus versus Thymus [GenomeTiling_MRK851]


title: Testis versus Brain - thalamus [GenomeTiling_MRK847]


title: Testis versus Brain - thalamus [GenomeTiling_MRK849]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK875]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK854]


title: Testis versus Brain - thalamus [GenomeTiling_MRK851]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK860]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK855]


title: Uterus versus Thymus [GenomeTiling_MRK852]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK847]


title: Uterus versus Thymus [GenomeTiling_MRK847]


title: Testis versus Brain - thalamus [GenomeTiling_MRK860]


title: Uterus versus Thymus [GenomeTiling_MRK857]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK851]


title: Uterus versus Thymus [GenomeTiling_MRK848]


title: Uterus versus Thymus [GenomeTiling_MRK855]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK852]


title: Testis versus Brain - thalamus [GenomeTiling_MRK852]


title: Uterus versus Thymus [GenomeTiling_MRK859]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK853]


title: Testis versus Brain - thalamus [GenomeTiling_MRK840]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK850]


title: Testis versus Brain - thalamus [GenomeTiling_MRK850]


title: Uterus versus Thymus [GenomeTiling_MRK840]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK840]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK859]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK848]


title: Uterus versus Thymus [GenomeTiling_MRK846]


title: Testis versus Brain - thalamus [GenomeTiling_MRK859]


title: Uterus versus Thymus [GenomeTiling_MRK850]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK838]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK858]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK846]


title: Uterus versus Thymus [GenomeTiling_MRK836]


title: Uterus versus Thymus [GenomeTiling_MRK838]


title: Uterus versus Thymus [GenomeTiling_MRK835]


title: Uterus versus Thymus [GenomeTiling_MRK858]


title: Uterus versus Thymus [GenomeTiling_MRK845]


title: Testis versus Brain - thalamus [GenomeTiling_MRK836]


title: Uterus versus Thymus [GenomeTiling_MRK831]


title: Testis versus Brain - thalamus [GenomeTiling_MRK858]


title: Testis versus Brain - thalamus [GenomeTiling_MRK838]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK836]


title: Testis versus Brain - thalamus [GenomeTiling_MRK846]


title: Testis versus Brain - thalamus [GenomeTiling_MRK835]


title: Uterus versus Thymus [GenomeTiling_MRK849]


title: Testis versus Brain - thalamus [GenomeTiling_MRK845]


title: Testis versus Brain - thalamus [GenomeTiling_MRK831]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK841]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK831]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK835]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK845]


title: Testis versus Brain - thalamus [GenomeTiling_MRK839]


title: Uterus versus Thymus [GenomeTiling_MRK829]


title: Uterus versus Thymus [GenomeTiling_MRK837]


title: Uterus versus Thymus [GenomeTiling_MRK839]


title: Uterus versus Thymus [GenomeTiling_MRK844]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK834]


title: Testis versus Brain - thalamus [GenomeTiling_MRK844]


title: Testis versus Brain - thalamus [GenomeTiling_MRK834]


title: Uterus versus Thymus [GenomeTiling_MRK834]


title: Uterus versus Thymus [GenomeTiling_MRK833]


title: Uterus versus Thymus [GenomeTiling_MRK843]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK829]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK839]


title: Testis versus Brain - thalamus [GenomeTiling_MRK829]


title: Uterus versus Thymus [GenomeTiling_MRK841]


title: Testis versus Brain - thalamus [GenomeTiling_MRK833]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK844]


title: Testis versus Brain - thalamus [GenomeTiling_MRK837]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK837]


title: Uterus versus Thymus [GenomeTiling_MRK832]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK843]


title: Testis versus Brain - thalamus [GenomeTiling_MRK843]


title: Testis versus Brain - thalamus [GenomeTiling_MRK832]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK842]


title: Uterus versus Thymus [GenomeTiling_MRK820]


title: Testis versus Brain - thalamus [GenomeTiling_MRK830]


title: Uterus versus Thymus [GenomeTiling_MRK842]


title: Testis versus Brain - thalamus [GenomeTiling_MRK822]


title: Uterus versus Thymus [GenomeTiling_MRK819]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK832]


title: Uterus versus Thymus [GenomeTiling_MRK824]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK833]


title: Testis versus Brain - thalamus [GenomeTiling_MRK842]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK830]


title: Testis versus Brain - thalamus [GenomeTiling_MRK824]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK820]


title: Uterus versus Thymus [GenomeTiling_MRK815]


title: Uterus versus Thymus [GenomeTiling_MRK830]


title: Testis versus Brain - thalamus [GenomeTiling_MRK820]


title: Uterus versus Thymus [GenomeTiling_MRK828]


title: Testis versus Brain - thalamus [GenomeTiling_MRK819]


title: Uterus versus Thymus [GenomeTiling_MRK822]


title: Testis versus Brain - thalamus [GenomeTiling_MRK828]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK822]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK824]


title: Testis versus Brain - thalamus [GenomeTiling_MRK815]


title: Testis versus Brain - thalamus [GenomeTiling_MRK841]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK827]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK815]


title: Uterus versus Thymus [GenomeTiling_MRK821]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK828]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK823]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK818]


title: Uterus versus Thymus [GenomeTiling_MRK813]


title: Testis versus Brain - thalamus [GenomeTiling_MRK818]


title: Testis versus Brain - thalamus [GenomeTiling_MRK823]


title: Uterus versus Thymus [GenomeTiling_MRK823]


title: Uterus versus Thymus [GenomeTiling_MRK826]


title: Uterus versus Thymus [GenomeTiling_MRK827]


title: Testis versus Brain - thalamus [GenomeTiling_MRK813]


title: Uterus versus Thymus [GenomeTiling_MRK817]


title: Uterus versus Thymus [GenomeTiling_MRK818]


title: Testis versus Brain - thalamus [GenomeTiling_MRK821]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK819]


title: Testis versus Brain - thalamus [GenomeTiling_MRK826]


title: Testis versus Brain - thalamus [GenomeTiling_MRK817]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK821]


title: Testis versus Brain - thalamus [GenomeTiling_MRK827]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK826]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK817]


title: Uterus versus Thymus [GenomeTiling_MRK806]


title: Uterus versus Thymus [GenomeTiling_MRK825]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK806]


title: Testis versus Brain - thalamus [GenomeTiling_MRK816]


title: Uterus versus Thymus [GenomeTiling_MRK814]


title: Testis versus Brain - thalamus [GenomeTiling_MRK848]


title: Testis versus Brain - thalamus [GenomeTiling_MRK806]


title: Uterus versus Thymus [GenomeTiling_MRK816]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK813]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK825]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK814]


title: Testis versus Brain - thalamus [GenomeTiling_MRK814]


title: Uterus versus Thymus [GenomeTiling_MRK812]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK816]


title: Uterus versus Thymus [GenomeTiling_MRK811]


title: Uterus versus Thymus [GenomeTiling_MRK803]


title: Uterus versus Thymus [GenomeTiling_MRK804]


title: Testis versus Brain - thalamus [GenomeTiling_MRK812]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK804]


title: Testis versus Brain - thalamus [GenomeTiling_MRK803]


title: Testis versus Brain - thalamus [GenomeTiling_MRK811]


title: Testis versus Brain - thalamus [GenomeTiling_MRK804]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK812]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK811]


title: Uterus versus Thymus [GenomeTiling_MRK807]


title: Thymus versus Uterus [GenomeTiling_MRK336]


title: Uterus versus Thymus [GenomeTiling_MRK336]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK803]


title: Testis versus Brain - thalamus [GenomeTiling_MRK336]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK336]

source_name: Spleen

source_name: Kidney - fetal


title: Testis versus Brain - thalamus [GenomeTiling_MRK802]


title: Uterus versus Thymus [GenomeTiling_MRK805]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK807]


title: Uterus versus Thymus [GenomeTiling_MRK810]


title: Testis versus Brain - thalamus [GenomeTiling_MRK807]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK802]


title: Uterus versus Thymus [GenomeTiling_MRK802]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK336]


title: Uterus versus Thymus [GenomeTiling_MRK809]


title: Testis versus Brain - thalamus [GenomeTiling_MRK810]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK336]


title: Uterus versus Thymus [GenomeTiling_MRK801]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK336]


title: Testis versus Brain - thalamus [GenomeTiling_MRK801]


title: Testis versus Brain - thalamus [GenomeTiling_MRK805]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK809]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK805]


title: Testis versus Brain - thalamus [GenomeTiling_MRK808]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK808]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK801]


title: Uterus versus Thymus [GenomeTiling_MRK337]


title: Testis versus Brain - thalamus [GenomeTiling_MRK809]


title: Uterus versus Thymus [GenomeTiling_MRK808]


title: Uterus versus Thymus [GenomeTiling_MRK335]


title: Testis versus Brain - thalamus [GenomeTiling_MRK825]


title: Brain - thalamus versus Testis [GenomeTiling_MRK336]


title: Uterus versus Thymus [GenomeTiling_MRK334]


title: Thymus versus Uterus [GenomeTiling_MRK337]


title: Thymus versus Uterus [GenomeTiling_MRK335]


title: Thymus versus Uterus [GenomeTiling_MRK334]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK337]


title: Testis versus Brain - thalamus [GenomeTiling_MRK334]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK335]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK334]


title: Thymus versus Uterus [GenomeTiling_MRK332]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK335]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK337]


title: Testis versus Brain - thalamus [GenomeTiling_MRK335]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK335]


title: Uterus versus Thymus [GenomeTiling_MRK332]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK337]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK334]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK335]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK334]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK332]


title: Brain - thalamus versus Testis [GenomeTiling_MRK335]


title: Testis versus Brain - thalamus [GenomeTiling_MRK337]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK334]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK810]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK337]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK332]


title: Brain - thalamus versus Testis [GenomeTiling_MRK334]


title: Thymus versus Uterus [GenomeTiling_MRK333]


title: Brain - thalamus versus Testis [GenomeTiling_MRK337]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK332]


title: Thymus versus Uterus [GenomeTiling_MRK321]


title: Testis versus Brain - thalamus [GenomeTiling_MRK333]


title: Thymus versus Uterus [GenomeTiling_MRK325]


title: Testis versus Brain - thalamus [GenomeTiling_MRK325]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK332]


title: Thymus versus Uterus [GenomeTiling_MRK331]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK333]


title: Uterus versus Thymus [GenomeTiling_MRK325]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK325]


title: Uterus versus Thymus [GenomeTiling_MRK321]


title: Uterus versus Thymus [GenomeTiling_MRK331]


title: Testis versus Brain - thalamus [GenomeTiling_MRK321]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK325]


title: Testis versus Brain - thalamus [GenomeTiling_MRK331]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK333]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK321]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK333]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK325]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK331]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK331]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK333]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK321]


title: Uterus versus Thymus [GenomeTiling_MRK324]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK325]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK321]


title: Brain - thalamus versus Testis [GenomeTiling_MRK325]


title: Thymus versus Uterus [GenomeTiling_MRK324]


title: Brain - thalamus versus Testis [GenomeTiling_MRK333]


title: Brain - thalamus versus Testis [GenomeTiling_MRK321]


title: Thymus versus Uterus [GenomeTiling_MRK323]


title: Uterus versus Thymus [GenomeTiling_MRK333]


title: Uterus versus Thymus [GenomeTiling_MRK328]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK321]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK331]


title: Uterus versus Thymus [GenomeTiling_MRK320]


title: Uterus versus Thymus [GenomeTiling_MRK323]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK331]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK323]


title: Brain - thalamus versus Testis [GenomeTiling_MRK331]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK324]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK320]


title: Thymus versus Uterus [GenomeTiling_MRK320]


title: Testis versus Brain - thalamus [GenomeTiling_MRK324]


title: Testis versus Brain - thalamus [GenomeTiling_MRK328]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK324]


title: Testis versus Brain - thalamus [GenomeTiling_MRK320]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK320]


title: Thymus versus Uterus [GenomeTiling_MRK328]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK320]


title: Testis versus Brain - thalamus [GenomeTiling_MRK323]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK324]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK320]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK328]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK323]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK323]


title: Brain - thalamus versus Testis [GenomeTiling_MRK324]


title: Brain - thalamus versus Testis [GenomeTiling_MRK320]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK323]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK324]


title: Brain - thalamus versus Testis [GenomeTiling_MRK323]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK328]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK328]


title: Uterus versus Thymus [GenomeTiling_MRK316]


title: Uterus versus Thymus [GenomeTiling_MRK322]


title: Thymus versus Uterus [GenomeTiling_MRK319]


title: Testis versus Brain - thalamus [GenomeTiling_MRK319]


title: Brain - thalamus versus Testis [GenomeTiling_MRK328]


title: Uterus versus Thymus [GenomeTiling_MRK327]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK328]


title: Thymus versus Uterus [GenomeTiling_MRK322]


title: Uterus versus Thymus [GenomeTiling_MRK319]


title: Testis versus Brain - thalamus [GenomeTiling_MRK316]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK319]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK316]


title: Thymus versus Uterus [GenomeTiling_MRK327]


title: Thymus versus Uterus [GenomeTiling_MRK316]


title: Testis versus Brain - thalamus [GenomeTiling_MRK322]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK322]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK322]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK316]


title: Testis versus Brain - thalamus [GenomeTiling_MRK327]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK319]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK327]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK319]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK319]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK327]


title: Brain - thalamus versus Testis [GenomeTiling_MRK322]


title: Brain - thalamus versus Testis [GenomeTiling_MRK319]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK327]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK316]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK322]


title: Brain - thalamus versus Testis [GenomeTiling_MRK327]


title: Uterus versus Thymus [GenomeTiling_MRK318]


title: Testis versus Brain - thalamus [GenomeTiling_MRK317]


title: Thymus versus Uterus [GenomeTiling_MRK326]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK327]


title: Uterus versus Thymus [GenomeTiling_MRK317]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK322]


title: Uterus versus Thymus [GenomeTiling_MRK314]


title: Thymus versus Uterus [GenomeTiling_MRK317]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK318]


title: Thymus versus Uterus [GenomeTiling_MRK314]


title: Uterus versus Thymus [GenomeTiling_MRK326]


title: Testis versus Brain - thalamus [GenomeTiling_MRK314]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK326]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK318]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK326]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK314]


title: Testis versus Brain - thalamus [GenomeTiling_MRK318]


title: Thymus versus Uterus [GenomeTiling_MRK318]


title: Brain - thalamus versus Testis [GenomeTiling_MRK316]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK317]


title: Brain - thalamus versus Testis [GenomeTiling_MRK317]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK316]


title: Testis versus Brain - thalamus [GenomeTiling_MRK326]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK317]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK317]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK326]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK317]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK318]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK326]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK314]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK318]


title: Uterus versus Thymus [GenomeTiling_MRK284]


title: Thymus versus Uterus [GenomeTiling_MRK284]


title: Brain - thalamus versus Testis [GenomeTiling_MRK326]


title: Thymus versus Uterus [GenomeTiling_MRK280]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK314]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK315]


title: Thymus versus Uterus [GenomeTiling_MRK315]


title: Thymus versus Uterus [GenomeTiling_MRK313]


title: Brain - thalamus versus Testis [GenomeTiling_MRK314]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK284]


title: Testis versus Brain - thalamus [GenomeTiling_MRK280]


title: Testis versus Brain - thalamus [GenomeTiling_MRK315]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK315]


title: Brain - thalamus versus Testis [GenomeTiling_MRK318]


title: Uterus versus Thymus [GenomeTiling_MRK280]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK284]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK314]


title: Testis versus Brain - thalamus [GenomeTiling_MRK313]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK315]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK280]


title: Uterus versus Thymus [GenomeTiling_MRK315]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK284]


title: Uterus versus Thymus [GenomeTiling_MRK313]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK280]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK315]


title: CL: Leukemia Chronic Myelogenous (K562) versus T lymphocyte (Jurkat) [GenomeTiling_MRK313]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK284]


title: Testis versus Brain - thalamus [GenomeTiling_MRK284]


title: Spleen versus Kidney - fetal [GenomeTiling_MRK313]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK280]


title: Kidney - fetal versus Spleen [GenomeTiling_MRK280]


title: Brain - thalamus versus Testis [GenomeTiling_MRK280]


title: Brain - thalamus versus Testis [GenomeTiling_MRK315]


title: T lymphocyte (Jurkat) versus CL: Leukemia Chronic Myelogenous (K562) [GenomeTiling_MRK313]


title: Brain - thalamus versus Testis [GenomeTiling_MRK284]


title: Thymus versus Uterus [GenomeTiling_MRK279]